TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25485857

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 0
Study: 23673091

Group type: EXPERIMENTAL
Intervention: Low temperature (LT) group: 36.0 - 37.5°C
Number of subjects: 65

Group type: COMPARATOR
Intervention: High temperature (HT) group: 37.5 - 38.3°C
Number of subjects: 65
Study: 21239867

Group type: EXPERIMENTAL
Intervention: E170 insulin assay
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Measurement of free insulin after PEG pre-treatment
Number of subjects: 77
Study: 18434058

Group type: EXPERIMENTAL
Intervention: 1.5T magnetic field strength
Number of subjects: 16

Group type: COMPARATOR
Intervention: 3T magnetic field strength
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.5T and 3T magnetic field strengths
Number of subjects: 16
Study: 16401537

Group type: EXPERIMENTAL
Intervention: SaphLITE retractor system (group III)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Conventional bridge technique (group II)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard continuous skin incisions (group I)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 110
Study: 12938815

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg per day
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 261
Study: 10993031

Group type: EXPERIMENTAL
Intervention: HRT alone (micronized E2 0.5 mg + micronized P4 100 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: HRT + T (micronized E2 0.5 mg + micronized P4 100 mcg + micronized T 1.25 mg)
Number of subjects: 57
Study: 9441115

Group type: EXPERIMENTAL
Intervention: MCT Accelerator
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3% saline alone
Number of subjects: 15
Study: 1349485

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 53

Group type: COMPARATOR
Intervention: 20 mg nitrendipine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Casual blood pressure readings
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure
Number of subjects: 53
Study: 3909323

Group type: EXPERIMENTAL
Intervention: Aztreonam (1-g or 2-g intravenous doses, three times daily for at least five days)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 226

Group type: COMPARATOR
Intervention: Tobramycin (administered to a group of 34 patients)
Number of subjects: 226
Study: 31243574

Group type: EXPERIMENTAL
Intervention: Drain (group A, n = 69)
Number of subjects: 136

Group type: COMPARATOR
Intervention: No drain (group B, n = 67)
Number of subjects: 136
Study: 29415754

Group type: EXPERIMENTAL
Intervention: Guanxinning tablet (GXNT) plus aspirin for 12 months
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Aspirin alone for 12 months
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Guanxinning tablet (GXNT) plus aspirin
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3600
Study: 27488394

Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 114
Study: 25399975

Group type: EXPERIMENTAL
Intervention: Danhong Injection
Number of subjects: 120
Study: 23597225

Group type: EXPERIMENTAL
Intervention: APF (1.23% acidulated phosphate fluoride gel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NNaF (2% neutral sodium fluoride gel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both APF and NNaF
Number of subjects: 0
Study: 21038764

Group type: EXPERIMENTAL
Intervention: kiR-Plus intervention in 5th grade
Number of subjects: 1984

Group type: EXPERIMENTAL
Intervention: kiR-AE intervention in both 5th and 7th grades
Number of subjects: 1984

Group type: COMPARATOR
Intervention: Control group (comparison schools' programming)
Number of subjects: 1984
Study: 18218825

Group type: EXPERIMENTAL
Intervention: Implantable peroneal nerve stimulator (FES) for 6 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 29
Study: 16734505

Group type: EXPERIMENTAL
Intervention: Calcipotriene cream group
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Alternating group
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Calcipotriene cream vs Vehicle
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Alternating vs Vehicle
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Calcipotriene cream vs Vehicle (adverse reactions)
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Alternating vs Vehicle (adverse reactions)
Number of subjects: 1136
Study: 14601366

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg intravenous upon anesthetic induction, every 4 hours during surgery, and every 8 hours for 48 hours post-surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 20
Study: 11458309

Group type: EXPERIMENTAL
Intervention: Temperament and Character Inventory (TCI)
Number of subjects: 156
Study: 9510902

Group type: EXPERIMENTAL
Intervention: School-based programs focusing on adolescent health problems
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Community health promotion projects
Number of subjects: 11
Study: 8167383

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2892988

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement administered for eight months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo administered for eight months
Number of subjects: 90

Group type: COMPARATOR
Intervention: No tablets taken
Number of subjects: 90
Study: 31758663

Group type: EXPERIMENTAL
Intervention: Learning collaborative intervention group focused on a treat‐to‐target approach
Number of subjects: 554

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Learning collaborative intervention group
Number of subjects: 554
Study: 31664959

Group type: EXPERIMENTAL
Intervention: SmokeFree Buddy app (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific app mentioned)
Number of subjects: 0
Study: 28485023

Group type: EXPERIMENTAL
Intervention: High-dose rituximab (HD-R) 1000 mg/m2
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard-dose rituximab (SD-R) 375 mg/m2
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patients in complete remission (CR) before ASCT
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patients with ≤2 lines of treatment prior to SCT
Number of subjects: 93
Study: 26362286

Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg orally once daily (with dose escalation by 500‐mg increments every 13 weeks, ending with 1,000 mg twice daily)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Resveratrol treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 23870300

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab therapy
Number of subjects: 353

Group type: COMPARATOR
Intervention: Quarterly ranibizumab therapy
Number of subjects: 353
Study: 21608442

Group type: EXPERIMENTAL
Intervention: Myo-Inositol 2 g twice a day
Number of subjects: 84

Group type: COMPARATOR
Intervention: D-chiro inositol 0.6 g twice a day
Number of subjects: 84
Study: 19366435

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of M-M-RvaxPro and VARIVAX
Number of subjects: 752

Group type: COMPARATOR
Intervention: Subcutaneous administration of M-M-RvaxPro and VARIVAX
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Intramuscular administration
Number of subjects: 752

Group type: COMPARATOR
Intervention: Subcutaneous administration
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 752
Study: 16482079

Group type: EXPERIMENTAL
Intervention: Fish protein meal
Number of subjects: 23

Group type: COMPARATOR
Intervention: Beef protein meal
Number of subjects: 23
Study: 15516942

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (no G-CSF)
Number of subjects: 117
Study: 11346153

Group type: EXPERIMENTAL
Intervention: Descalating dose of interferon-alpha-2a; six million units thrice weekly for 24 weeks followed by 3 MIU 3x for 24 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Interferon-alpha-2a (3 million units thrice weekly for 24 weeks) plus ribavirin (1,000 mg/day for 12 weeks)
Number of subjects: 32
Study: 9214527

Group type: EXPERIMENTAL
Intervention: Pramipexole 1.5 mg/d
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Pramipexole 3.0 mg/d
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Pramipexole 4.5 mg/d
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Pramipexole 6.0 mg/d
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Pramipexole (all doses combined)
Number of subjects: 264
Study: 7525517

Group type: EXPERIMENTAL
Intervention: Ondansetron (Group C)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nonondansetron antiemetics (Group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No pretreatment antiemetics (Group A)
Number of subjects: 41
Study: 31262767

Group type: COMPARATOR
Intervention: SPR741, 5 to 800 mg single doses; 50 to 600 mg multiple doses every 8 hours for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: SPR741, 400 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPR741, up to 1,800 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPR741, multiple doses
Number of subjects: 0
Study: 30381621

Group type: EXPERIMENTAL
Intervention: Intravenous l-carnitine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous branched-chain amino acids (BCAA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral l-carnitine supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional agents (lactulose and non-absorbable antibiotics)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Blood ammonia levels
Number of subjects: 45
Study: 27106272

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Reference treatment
Number of subjects: 44
Study: 25282165

Group type: EXPERIMENTAL
Intervention: High-risk surgical patients (HR)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Non-high-risk surgical patients (non-HR)
Number of subjects: 698
Study: 22284318

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nerve stimulator guidance
Number of subjects: 45
Study: 19577936

Group type: EXPERIMENTAL
Intervention: Pio plus the American Diabetes Association diet (Pio+ADA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pio plus a portion control weight loss diet (Pio+PC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: metformin plus ADA diet (Met+ADA)
Number of subjects: 51
Study: 18922381

Group type: EXPERIMENTAL
Intervention: Waon therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study: 16022970

Group type: EXPERIMENTAL
Intervention: Manual thrombus-aspiration
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 99
Study: 12458654

Group type: EXPERIMENTAL
Intervention: Candesartan 8 or 16 mg
Number of subjects: 968
Study: 10520057

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) aqueous nasal spray, 200 microg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levocabastine (LEV) nasal spray, 200 microg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLA) nasal spray
Number of subjects: 24
Study: 8559985

Group type: EXPERIMENTAL
Intervention: Misoprostol (100 mcg intravaginally)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin (2‐32 mU/min IV)
Number of subjects: 100
Study: 1791485

Group type: EXPERIMENTAL
Intervention: Enalapril (an angiotensin converting enzyme inhibitor)
Number of subjects: 13000
Study: 30203840

Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) prevention trial
Number of subjects: 517

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 517
Study: 28830204

Group type: EXPERIMENTAL
Intervention: Theory‐driven, home‐based, self‐help parenting program
Number of subjects: 577

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 577
Study: 27426699

Group type: EXPERIMENTAL
Intervention: CES with 200 mg caffeine (CAF2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CES with 100 mg caffeine (CAF1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study: 25122031

Group type: EXPERIMENTAL
Intervention: 12-week individually tailored, motivationally matched exercise intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Health and wellness intervention
Number of subjects: 260
Study: 22982471

Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (480 mg/day for 6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (960 mg/day for 5 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (single and 14-day repeat dosing in rats and dogs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (highest dose level in dogs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (rat and dog studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reverse mutation assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (general findings)
Number of subjects: 0
Study: 19889523

Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Specialized care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 150
Study: 18001210

Group type: EXPERIMENTAL
Intervention: 80 mg purified isoflavones for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 53
Study: 15533544

Group type: EXPERIMENTAL
Intervention: Proactive telephone support with nicotine patches
Number of subjects: 330

Group type: COMPARATOR
Intervention: Nicotine patches (control condition)
Number of subjects: 330
Study: 12015500

Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol 12 and 24 hours before surgery
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol
Number of subjects: 204
Study: 10213125

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5mg twice a day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no calcitriol)
Number of subjects: 34
Study: 8574714

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice daily for 1 week (Phase 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole twice daily for 1 week (Group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole daily for 1 week (Group B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No omeprazole for 1 week (Group C)
Number of subjects: 200
Study: 2192985

Group type: EXPERIMENTAL
Intervention: CDDP 50 mg/mq + alizapride
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CDDP 50 mg/mq + metoclopramide
Number of subjects: 75

Group type: COMPARATOR
Intervention: CDDP 50 mg/mq + placebo
Number of subjects: 75
Study: 393299

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combined preparations containing oestrogen and progestogen
Number of subjects: 56
Study: 29437489

Group type: EXPERIMENTAL
Intervention: Daily text message reminders for 30 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups received electronic sensors to measure ICS use
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Caregivers who completed the acceptability survey
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Adherence trajectories
Number of subjects: 41
Study: 30388775

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate and potassium bicarbonate fortified with minerals, ingested twice a day over a nine-day training period.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 26
Study: 27468541

Group type: EXPERIMENTAL
Intervention: Integrated Traditional Chinese Medicine (TCM) with basic treatment
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo with basic treatment
Number of subjects: 240
Study: 25117155

Group type: EXPERIMENTAL
Intervention: Hand sanitiser provision in classrooms
Number of subjects: 2443

Group type: COMPARATOR
Intervention: Control (usual hand hygiene education only)
Number of subjects: 2443
Study: 22893135

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide 20 mg
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study: 19373107

Group type: EXPERIMENTAL
Intervention: Phacoemulsification alone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Combined phaco-trabeculectomy
Number of subjects: 72
Study: 18076264

Group type: EXPERIMENTAL
Intervention: Vertec device with squat jump protocol
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Vertec device
Number of subjects: 95

Group type: COMPARATOR
Intervention: Just Jump device
Number of subjects: 95

Group type: COMPARATOR
Intervention: Countermovement jump protocol
Number of subjects: 95

Group type: COMPARATOR
Intervention: Squat jump protocol
Number of subjects: 95
Study: 16150197

Group type: EXPERIMENTAL
Intervention: Naohuandan (NHD), 4 capsules each time, 3 times daily for 3 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Piracetam, 1.6 g each time, 3 times daily for 3 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dosage NHD
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low-dosage NHD
Number of subjects: 58

Group type: COMPARATOR
Intervention: Model group (no treatment)
Number of subjects: 58
Study: 12871256

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once per week for 6 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo once per week for 6 months
Number of subjects: 110
Study: 10812040

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8642144

Group type: EXPERIMENTAL
Intervention: Pre-procedural subgingival irrigation and rinsing with an antiseptic mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 0
Study: 1619099

Group type: EXPERIMENTAL
Intervention: Behavior management training (n = 20)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Problem-solving and communication training (n = 21)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Structural family therapy (n = 20)
Number of subjects: 61

Group type: COMPARATOR
Intervention: All treatments combined
Number of subjects: 61
Study: 6531953

Group type: EXPERIMENTAL
Intervention: Trivalent subunit influenza virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trivalent split vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study: 31469675

Group type: EXPERIMENTAL
Intervention: Mitomycin C-augmented phacotrabeculectomy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy
Number of subjects: 63
Study: 26297091

Group type: EXPERIMENTAL
Intervention: Ditto intervention (n = 35)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard practice (n = 40)
Number of subjects: 75
Study: 24338229

Group type: EXPERIMENTAL
Intervention: Yoga breathing exercises for 8 weeks
Number of subjects: 120
Study: 22552505

Group type: EXPERIMENTAL
Intervention: Short-term antibiotic prophylaxis (single dose)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Long-term antibiotic prophylaxis (multiple dose)
Number of subjects: 527
Study: 19414832

Group type: EXPERIMENTAL
Intervention: Stent placement and medical treatment (64 patients)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Medical treatment only (76 patients)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Stent placement with medical treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 140
Study: 18089250

Group type: EXPERIMENTAL
Intervention: Self-esteem threat with false failure feedback and exposure to thin models
Number of subjects: 94

Group type: COMPARATOR
Intervention: Self-esteem threat with false success feedback and exposure to thin models
Number of subjects: 94
Study: 14971623

Group type: EXPERIMENTAL
Intervention: Mainly computer-guided self-exposure therapy (FearFighter)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Entirely clinician-guided self-exposure therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Self-relaxation (placebo)
Number of subjects: 93
Study: 11813272

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS) subscales
Number of subjects: 213
Study: 9805328

Group type: EXPERIMENTAL
Intervention: Shunted hydrocephalus group
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Arrested hydrocephalus group
Number of subjects: 157

Group type: COMPARATOR
Intervention: No hydrocephalus group
Number of subjects: 157
Study: 7924466

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (Naughton modified protocol, holding on handrails permitted)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bicycle exercise (10 W/min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bicycle exercise
Number of subjects: 40